MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .
MOUNTAIN VIEW, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in September: 20 th Annual Rodman & Renshaw Global Investment
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental Glomerulosclerosis (FSGS), diseases with no approved therapies -- -- Launch of clinical
MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2018 financial results will be released after market close on Thursday, August 9, 2018 . ChemoCentryx executive management will host a conference call and
MOUNTAIN VIEW, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Corporate
MOUNTAIN VIEW, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress , being held in collaboration with the Danish Society
-- Patient enrollment in Phase III ADVOCATE trial of avacopan in the treatment of ANCA-associated vasculitis exceeds 85%; Conditional Marketing Authorization (CMA) application under review with European Medicines Agency (EMA) -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G)
MOUNTAIN VIEW, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's first quarter 2018 financial results will be released after market close on Wednesday, May 9, 2018 . ChemoCentryx executive management will host a conference call and
MOUNTAIN VIEW, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of avacopan in the treatment
MOUNTAIN VIEW, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in April: H.C. Wainwright Global Life Sciences Conference Monday,
